AN2 Therapeutics, Inc.ANTX

$5.00+0.10 (+2.04%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$170M

Micro-cap

-49%

2022 — today

10-Year Price

-73%

2022 — today

52-Week Range

$1.03$5.46

Current $5.00· 90%

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Valuation in context

P/E ratio

-4.5

N/A

Not meaningful — company is unprofitable

P/B ratio

2.1

Above average

Pricier than usual over the last 10 years

FCF Yield

-18.4%

Above average

Above the 10-year average

Free · No credit card needed

Get alerted when ANTX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.